Teleflex, a global provider of medical devices for critical care and surgery, announced that its ARROW Endurance Extended Dwell Peripheral Catheter System received market clearance from the US Food and Drug Administration (FDA).
The new device is a peripheral catheter system in which the catheter is cleared by the FDA to dwell up to 29 days.
The extended dwell catheter enables hospitals to avoid using multiple PIVs to achieve longer dwell times while also avoiding the extra clinical risks and expenses associated with a peripherally inserted central catheter (PICC).
The intravascular catheter is intended for short-term use (up to 29 days) to permit delivery of infusion therapies, pressure monitoring, high pressure injection (325 psi max.), and withdrawal of blood.
"The ARROW Endurance Extended Dwell Peripheral Catheter System is yet another offering from Teleflex that helps vascular access professionals provide the right line for the right patient at the right time," said Jay White, president of Teleflex’s Vascular Access Division.
"This is the ideal solution when patients need IV therapy for more than the few days that a traditional PIV allows but don’t require a PICC."
Designed to maximize performance and ease-of-use, the extended dwell system is engineered to increase safety for clinicians and reduce needle sticks for patients.
The device contains a passive needle safety that reduces the risk of accidental needle stick injuries and exposure to blood. The closed system design makes it less likely that clinicians will accidentally come in contact with bloodborne pathogens.
Teleflex expects to launch the ARROW Endurance Extended Dwell Peripheral Catheter System in the US later this year.
Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety.